Bio-Rad Laboratories (BIO) Q2 2024 earnings summary

Executive summary

• Q2 2024 net sales were $638.5 million, down 6.3% year-over-year, mainly due to Life Science segment weakness, while gross margin improved to 55.6% from 53.2% on cost controls and product mix.

• Life Science segment sales fell 16.5% year-over-year, driven by process chromatography destocking and weak biopharma demand; Clinical Diagnostics grew 2.1% with broad-based gains and higher demand for quality controls and blood typing.

• Q2 2024 GAAP net loss was $2.17 billion, primarily due to a $2.87 billion holding loss on Sartorius AG equity; non-GAAP net income was $89 million ($3.11/share), flat year-over-year.

• Share repurchases totaled $100 million in Q2 and $96 million in July, with an additional $500 million authorized, bringing total available to $578 million.

• Leadership transitions continued, with new heads for Life Science and Clinical Diagnostics and COO search nearing completion.

Financial highlights

• Q2 2024 net sales: $638.5 million (down 6.3% year-over-year); currency-neutral decline of 5.4%.

• Life Science: $250.5 million (down 16.5%); Clinical Diagnostics: $387.9 million (up 2.1%).

• GAAP gross margin: 55.6% (up from 53.2%); non-GAAP gross margin: 56.4%.

• Operating income: $101.5 million (15.9% of sales), up from $89.6 million (13.2%).

• Non-GAAP net income: $89 million ($3.11/share), flat year-over-year.

• Reported net loss: $2.17 billion, driven by a $2.87 billion loss in Sartorius AG equity.

• Free cash flow: $55 million, down from $63 million year-over-year.

Outlook and guidance

• 2024 revenue now expected to decline 2.5%-4% year-over-year, revised from prior growth estimate.

• H2 2024 revenue expected to grow 2% year-over-year and 6% sequentially over H1.

• Life Science revenue to decline 10%-12% for 2024; excluding process chromatography, decline expected at 4%.

• Clinical Diagnostics revenue to grow 3%-3.5% for 2024.

• Non-GAAP gross margin projected at 54.5%-55%; operating margin at 12%-13%; adjusted EBITDA margin at 18%-19%.

• One-time in-process R&D charge of ~$30 million expected in Q3 or by year-end.

• Management anticipates a slower market recovery in biotech and biopharma sectors.